Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
Rail customers expect to be served by trains that function perfectly from the very first day of service. This is particularly true for the new Intercity…
According to the International Diabetes Federation (IDF), diabetes affects close to 400 million people worldwide and caused 500 billion Euros in health expenditure in 2013. In preclinical and clinical trials, the NMDA receptor antagonist dextrorphan (DXO) and its prodrug dextromethorphan have been shown to harbor antidiabetic properties (Marquard et al., Nat Med 2015). In addition, DXO was shown to protect mouse and human pancreatic beta cells from cell death during a diabetogenic setting.
DXO is well tolerated and sold as over-the-counter (OTC) medication for more than 50 years. However, adverse events are observed, which are likely caused by the action of DXO on the central nervous system (CNS). Here, the scientists developed DXO-derivatives that do not efficiently pass the blood brain barrier (BBB), and thus should cause fewer adverse effects on the CNS, but maintain their antidiabetic properties. Therefore, the derivatives might maintain the good safety profile and antidiabetic properties of its starting substance dextrorphan, but with fewer adverse effects.
The inventors now aim to demonstrate the expected novel clinical benefit in clinical studies.
The present invention refers to a method and a device for improving a person‘s mobility. It is designed as a mobile, technical platform offering space for one person being moved with power assistance.
In contrast to the already known mobility equipment, the technical basis of the inventive mobility platform consists of “rolling legs“ known as whegs (“wheg“ = wheel-like leg / wheel a leg / wheel-legs). These whegs combine the positive features of wheels and legs. To antagonize disturbing effects of alternation, a force coupled mechanical solution is applied.
A multicenter research team has identified a biomarker that predicts which stage II colon cancer patients may benefit from chemotherapy after surgery to…
Scientists of the international ALPHA Collaboration have once again pushed the boundaries of antimatter research with their latest breakthrough studying the…
“This is a real bombshell in the field of neuroscience,” says Terry Sejnowski, Salk professor and co-senior author of the paper, which was published in eLife….